IUI versus IVF: clinical pathways for fertility success
When you are choosing between intrauterine insemination (IUI) and in vitro fertilization (IVF), the headline success rate can make the decision seem straightforward.
IVF generally has a higher chance of pregnancy or live birth per treatment cycle, but it also involves more medication, procedures, time, and expense. IUI is less invasive and may be a reasonable first step for some diagnoses, yet its chances depend strongly on age and the reason conception has been difficult.
The right comparison is therefore not a single percentage. It is the likelihood of success for your age and diagnosis, weighed against how much time you have, what treatment asks of your body, and what you can realistically manage. We can use the evidence to map the options, while keeping in view that no population average predicts an individual outcome on its own.
What happens in IUI and IVF
IUI places prepared sperm into the uterus around the time of ovulation. The sperm still need to travel through the reproductive tract and fertilize an egg; fertilization and early embryo development take place inside the body. Depending on the clinical plan, IUI may be timed with a natural cycle or combined with medication to stimulate ovulation.
IVF moves several steps into the laboratory. Medication stimulates the ovaries to develop multiple eggs. After egg retrieval, eggs are fertilized with sperm, and an embryo is transferred into the uterus. Any additional suitable embryos may sometimes be frozen for later use, depending on the clinical situation and treatment plan.
That difference matters when we interpret success rates. An IUI cycle offers one opportunity for fertilization in that cycle, while IVF involves egg retrieval, fertilization, and embryo selection before transfer. The reported outcome may also refer to different endpoints: a positive pregnancy test, a clinical pregnancy, or a live birth. When comparing clinic figures, check which outcome is being counted and whether the denominator is a treatment cycle, an embryo transfer, or a patient over multiple attempts.
| Treatment feature | IUI | IVF |
|---|---|---|
| Where fertilization happens | Inside the body | In the laboratory |
| Main steps | Ovulation timing and placement of prepared sperm in the uterus | Ovarian stimulation, egg retrieval, fertilization, and embryo transfer |
| Typical treatment burden | Fewer procedures; medication may or may not be used | More medication, monitoring, and procedures |
| Relative success per cycle | Lower overall; strongly affected by age and diagnosis | Higher per cycle, especially in younger patients, though individual outcomes vary |
| Common role in care | A possible initial option for selected diagnoses | Often favored when IUI is unlikely to work well or time is a major concern |
IUI does not bypass blocked fallopian tubes: sperm and egg still need to meet in the reproductive tract. IVF can bypass that barrier because fertilization occurs outside the body. This is one reason the diagnosis can matter as much as the age-based success figures.
The useful question is not simply which treatment has the higher rate. It is which route gives you a meaningful chance within the time and clinical circumstances you have.
How success rates change with age
The available figures show a consistent pattern: IUI success per cycle generally falls with age, while IVF live birth rates are higher per cycle for many patients, particularly those under 35. These are broad ranges, not personal predictions. Diagnosis, medication protocol, ovarian response, sperm factors, and the clinic’s reporting methods all affect what a rate means for you.
For IUI, reported success is approximately 15–20% per cycle for women under 35. The range falls to about 10–12% at ages 35–37, 7–10% at ages 38–40, and roughly 3–9% for women over 40. Across a wider mix of ages and treatment circumstances, IUI success is often described as ranging from 5% to 20% per cycle.
For IVF, the supplied evidence places live birth rates for women under 35 at approximately 40–60% per cycle. That figure should not be carried over to every age group or interpreted as a guarantee. National reporting, including CDC data, separates IVF outcomes into age bands because age is central to understanding the chance of success. The relevant age brackets include under 35, 35–37, 38–40, 41–42, and over 42.
| Age group | Approximate IUI success per cycle | IVF context |
|---|---|---|
| Under 35 | 15–20% | Reported IVF live birth rate is approximately 40–60% per cycle |
| 35–37 | 10–12% | Outcomes are reported separately for this age band |
| 38–40 | 7–10% | Outcomes are reported separately for this age band |
| Over 40 | Roughly 3–9% | CDC reporting distinguishes ages 41–42 from over 42 |
The table is a starting point, not a forecast. One clinic may report pregnancy per insemination, while another may emphasize live birth per cycle. IVF figures can be presented per egg retrieval or per embryo transfer, and those are not interchangeable. When someone says a treatment has a particular success rate, ask what outcome and time frame sit behind that number.
Age also affects the value of time spent trying one approach before moving to another. For a younger patient with a diagnosis suited to IUI, a short course of treatment may be a sensible trade-off. As age increases, the potential cost of repeating lower-probability cycles can become more important. That does not mean age alone dictates IVF; it means the plan should account for age alongside the rest of your fertility workup.
Why diagnosis can change the pathway
IUI is most useful when sperm can reach the egg and there is a reasonable chance of ovulation and fertilization. It may be considered for mild male-factor infertility, unexplained infertility, or situations where timed intercourse is difficult. Whether medication is used depends on your baseline, the clinical findings, and how the care team balances a chance of success against the risks of stimulation.
IVF may be prioritized when the biology makes IUI less likely to work. A significant tubal factor is a key example: IUI still depends on a functional route for sperm and egg to meet, whereas IVF allows fertilization to happen in the laboratory. Severe male-factor infertility may also lead a clinician to recommend IVF, sometimes with additional laboratory techniques. In these situations, starting with IUI can add cycles without addressing the main obstacle.
Before choosing a route, your care team will usually need enough information to understand that obstacle. The details vary, but the discussion commonly includes:
- Ovulation and ovarian reserve. Testing such as AMH can contribute to the picture of ovarian reserve, but it cannot by itself tell you whether you will conceive naturally or predict an exact IVF outcome. It needs to be interpreted with age, ultrasound findings, and clinical history.
- Fallopian tube patency. If a tube is blocked or there is another major tubal issue, the logic of IUI changes because the sperm and egg still need to meet inside the reproductive tract.
- Semen analysis. The degree and type of sperm-related findings help determine whether IUI is plausible or whether a laboratory-based approach is more appropriate.
- The broader fertility history. How long you have been trying, prior pregnancies or treatments, cycle patterns, and medical conditions can all affect the balance between trying IUI and moving sooner to IVF.
These findings do not produce a treatment choice automatically. They make the choice more specific. When a test result is uncertain or borderline, ask how it changes the estimated chance with IUI, and whether any further evaluation would alter the plan.
The three-to-four-cycle point
For many patients who are good candidates for IUI, clinicians reassess after three or four unsuccessful cycles rather than continuing indefinitely. This is often called the three-cycle rule, though the actual decision depends on your diagnosis, age, response to medication, and personal priorities.
A reassessment is useful even when IUI remains an option. The clinician can review whether ovulation occurred as expected, whether treatment timing was appropriate, and whether the diagnosis still supports another attempt. If the original plan used medication, the team may also consider whether a different protocol is justified. Repeating the same approach without revisiting the assumptions behind it can spend time without adding useful information.
A practical conversation can follow a clear sequence:
1. Review what each cycle actually achieved. Was ovulation confirmed? Was insemination timed appropriately? Did monitoring reveal anything that changes the original plan?
2. Update the prognosis. Ask how your age and current test results affect the estimated chance of another IUI cycle, rather than relying on the estimate given before treatment started.
3. Compare the next step with IVF. Discuss likely outcomes, treatment burden, timing, and cost for the options that fit your diagnosis.
4. Agree on a stopping point. Decide in advance how many additional IUI cycles would make sense and what finding would prompt a move to IVF.
A failed IUI does not prove that IVF will fail, and it does not mean you did anything wrong. It tells the team that this particular opportunity did not lead to pregnancy. After several attempts, the more important question is whether another cycle is likely to add enough value to justify the time and expense.
Reassessment is part of treatment, not a verdict on your body. It gives you and your clinician a chance to update the plan with what the cycles have shown.
What the FASTT study adds to the discussion
The FASTT study compared a pathway that moved eligible patients to IVF sooner with a pathway that continued IUI using controlled ovarian stimulation. In the reported IUI arms, pregnancy rates were 7.6% with clomiphene citrate and 9.8% with gonadotropins. The study reported lower cumulative costs in the immediate-IVF arm for specific patient groups.
That finding is useful, but its scope matters. It does not establish that IVF is cheaper for every patient, in every location, or under every insurance plan. Total cost depends on coverage, medication, clinic fees, the number of cycles, and what treatment is indicated. The study also compares particular pathways; its figures should not be treated as a universal estimate of what you will pay or achieve.
When cost is part of the decision, compare the full pathway rather than the price of a single appointment or procedure. Ask what is included in the quoted cycle, which medications are billed separately, and how your insurance handles IUI, IVF, monitoring, and embryo storage if relevant. A lower upfront cost per IUI cycle may not mean a lower total cost if several cycles are needed; conversely, IVF can carry substantial costs and may not be the right clinical choice for everyone.
Time belongs in that calculation too. If age or diagnosis makes repeated IUI less promising, the cost of delaying a more suitable treatment may matter alongside the financial cost. We cannot turn that into one rule for every patient. We can make it a visible part of the conversation rather than leaving it out.
Choosing a route with your clinician
Intrauterine insemination versus in vitro fertilization success rates are best understood as one part of a larger decision. IUI offers a lower-intervention pathway that can suit selected patients, especially when the underlying findings support it. IVF generally offers higher success per cycle and may be the clearer route when tubal disease, severe male-factor issues, or age-related time pressure changes the odds.
Your plan should connect three things: the diagnosis, the chance of live birth per treatment cycle, and the practical burden of each option. A useful appointment ends with more than a general recommendation. You should know what the team believes is driving infertility, what outcome they are measuring, how many IUI cycles they would consider reasonable, and what would trigger a change in direction.
The next question to ask your doctor is: “Given my age, test results, and diagnosis, what is the estimated chance of live birth with one more IUI cycle compared with moving to IVF now, and what assumptions are behind those estimates?”